Receptor Types and G-Protein Signalling

Drug receptors fall into a small number of structural and functional superfamilies, each with a characteristic mode of signal transduction. The largest and most heavily drugged is the G-protein-coupled receptor (GPCR) family, whose seven-transmembrane architecture couples ligand binding to intracellular G-proteins and second messengers; the other principal classes are ligand-gated ion channels, enzyme-linked (kinase) receptors, and intracellular nuclear receptors.

Definition

Receptor pharmacology is the study of the structural classes of drug receptors and the signal-transduction mechanisms - notably the G-protein-coupled receptor signalling cascade - by which receptor activation is converted into a cellular and physiological response.

Scope

This topic surveys the major receptor superfamilies and their signal-transduction logic, with emphasis on GPCRs and G-protein signalling. It covers receptor classification, the G-protein cycle and second-messenger cascades, the temporal contrast between fast ionotropic and slower metabotropic signalling, and concepts such as allosteric modulation, biased agonism, and desensitisation. It is a mechanistic reference entry, not clinical guidance.

Core questions

• What are the major receptor superfamilies and how do they differ?
• How does a G-protein-coupled receptor transduce a signal across the membrane?
• What second messengers carry the signal inside the cell?
• Why do ion-channel receptors act in milliseconds while GPCRs and nuclear receptors act more slowly?
• What are biased agonism and allosteric modulation, and why do they matter for drug design?

Key concepts

• Receptor superfamilies (GPCR, ligand-gated ion channel, kinase-linked, nuclear)
• Seven-transmembrane (7TM) architecture
• Heterotrimeric G-proteins (Gs, Gi, Gq)
• Second messengers (cAMP, IP3, diacylglycerol, calcium)
• Ionotropic versus metabotropic signalling
• Allosteric modulation and biased agonism
• Receptor desensitisation and internalisation

Key theories

Ternary complex and conformational selection

GPCR activation is described by equilibria among ligand, receptor, and G-protein in which agonists stabilise active receptor conformations; extensions of this model account for constitutive activity, inverse agonism, and biased signalling.

Mechanisms

Receptors are grouped by how they transduce signals. Ligand-gated ion channels (ionotropic receptors) open a pore within milliseconds of binding, producing fast synaptic signalling. GPCRs (metabotropic, seven-transmembrane receptors) couple agonist binding to a heterotrimeric G-protein, whose alpha and beta-gamma subunits then modulate effector enzymes and channels: Gs stimulates and Gi inhibits adenylyl cyclase to set cyclic AMP levels, while Gq activates phospholipase C to generate inositol trisphosphate and diacylglycerol and release intracellular calcium. Kinase-linked receptors transduce signals by phosphorylation cascades, and nuclear receptors bind lipophilic ligands intracellularly and act as ligand-regulated transcription factors over hours. Kenakin and Miller describe GPCRs as conformationally flexible proteins whose ligands can stabilise distinct active states, the basis of allosteric modulation and biased agonism; sustained activation triggers desensitisation and internalisation that limit and reshape the response.

Clinical relevance

A large share of marketed drugs act through GPCRs and the other receptor superfamilies, so understanding signal-transduction class helps explain why drugs have particular effect profiles and time courses. This entry is descriptive and educational and does not provide treatment or dosing recommendations.

Evidence & guidelines

Receptor nomenclature and classification follow the IUPHAR/BPS Guide to Pharmacology framework and IUPHAR quantitative-pharmacology terminology; mechanistic detail is consolidated in standard pharmacology references.

History

The biochemical dissection of G-protein signalling by Rodbell and Gilman in the 1970s-1980s, and the cloning and structural characterisation of adrenergic and other GPCRs by Lefkowitz and Kobilka, established the molecular picture of receptor signal transduction. These advances, recognised by Nobel Prizes in 1994 and 2012, turned receptor pharmacology from a phenomenological into a molecular science and underpinned the modern concepts of allosteric and biased signalling.

Debates

Can biased agonism deliver safer drugs?

Ligands that selectively engage some downstream pathways of a receptor while sparing others promise to separate therapeutic from adverse signalling, but translating biased signalling at the bench into reliable clinical benefit remains contested.

Key figures

• Robert Lefkowitz
• Brian Kobilka
• Alfred Gilman
• Martin Rodbell
• Terry Kenakin

Seminal works

• kenakin-2010
• gronemeyer-2004
• neubig-2003

Frequently asked questions

What makes G-protein-coupled receptors such common drug targets?

GPCRs form the largest receptor superfamily, sit at the cell surface where drugs can reach them, and control many physiological systems through versatile second-messenger signalling, which makes them accessible and high-impact targets.

How does a ligand-gated ion channel differ from a GPCR?

A ligand-gated ion channel opens a pore directly within milliseconds of binding (fast, ionotropic signalling), whereas a GPCR works indirectly through G-proteins and second messengers over a slower timescale (metabotropic signalling).